logo
At least four killed by Israeli fire near Gaza food point, officials say

At least four killed by Israeli fire near Gaza food point, officials say

Yahoo5 hours ago

At least four people have been killed and others injured by Israeli fire about a kilometre from a food distribution point in Gaza, Palestinian health officials and witnesses said, the latest casualties of a new system to provide supplies that critics say is unethical, chaotic and dangerous.
Palestinian witnesses said Israeli forces had opened fire on Sunday morning as people went to receive supplies from a site in Rafah run by the Gaza Humanitarian Foundation (GHF), an Israeli and US-backed group.
Israel's military said it had fired warning shots at people who had approached its forces. It acknowledged reports of injuries but did not specify how many people it believed had been affected.
Bodies were brought to Nasser hospital in Khan Younis. Al-Awda hospital said it had received the body of a 42-year-old man, as well as 29 people who had been injured near another GHF distribution point.
The Reuters news agency reported that four people had been killed by the Israeli fire, while the Associated Press put the death toll at 'at least' five.
The deaths bring the number of people who have been killed while trying to find food in Gaza since 27 May, when GHF became responsible for civilian food provision, to 110. More than 1,000 have been injured.
Witnesses said Sunday's shooting in southern Gaza occurred at about 6am, when they had been told the site would open. Many had headed towards it early to try to get desperately needed food before the crowds. The military had announced on Friday that the sites would be open from 6am and that the area would be a closed military zone from 6pm until 6am.
A GHF spokesperson said there had been 'no incident at or in [the] surrounding vicinity' of any distribution site.
Adham Dahman, 30, who was at Nasser hospital with a bandage on his chin, told Associated Press that a tank had fired in their direction. 'We didn't know how to escape,' he said. 'This is trap for us, not aid.'
Zahed Ben Hassan, another witness, said someone next to him had been shot in the head. He said he and others had pulled the body from the scene and managed to flee to the hospital.
'They said it was a safe area from 6am until 6pm … so why did they start shooting at us?' he said. 'There was light out, and they have their cameras and can clearly see us.'
Sanaa Doghmah told Reuters that her husband, Khaled, 36, was fatally shot in the head while trying to reach a distribution site in Rafah to collect food for their five children.
Khaled's aunt, Salwah, said at his funeral: 'He was going to get food for his children and himself, to make them live, feed them, because they don't have a pinch of flour at home.'
There have been frequent shootings in the past two weeks near the new hubs, where thousands of Palestinians are being directed to collect food.
Coverage of the war in Gaza is constrained by Israeli attacks on Palestinian journalists and a bar on international reporters entering the Gaza Strip to report independently on the war.
Israel has not allowed foreign reporters to enter Gaza since 7 October 2023, unless they are under Israeli military escort. Reporters who join these trips have no control over where they go, and other restrictions include a bar on speaking to Palestinians in Gaza.
Palestinian journalists and media workers inside Gaza have paid a heavy price for their work reporting on the war, with over 180 killed since the conflict began.
The committee to protect journalists has determined that at least 19 of them 'were directly targeted by Israeli forces in killings which CPJ classifies as murders'.
Foreign reporters based in Israel filed a legal petition seeking access to Gaza, but it was rejected by the supreme court on security grounds. Private lobbying by diplomats and public appeals by prominent journalists and media outlets have been ignored by the Israeli government.
To ensure accurate reporting from Gaza given these restrictions, the Guardian works with trusted journalists on the ground; our visual​​ teams verif​y photo and videos from third parties; and we use clearly sourced data from organisations that have a track record of providing accurate information in Gaza during past conflicts, or during other conflicts or humanitarian crises.
Emma Graham-Harrison, chief Middle East correspondent
The GHF announced on Wednesday that its operations would be suspended for 24 hours after Israeli troops opened fire on a crowd of Palestinians, as it pressed Israel to improve civilian safety beyond the perimeter of its distribution sites.
Israeli troops killed at least 27 people and injured hundreds on Tuesday far beyond the perimeter of the distribution sites. They denied firing at civilians, but an Israel Defense Forces official admitted soldiers had fired 'warning shots toward several suspects who advanced toward the troops' near the food distribution site, without specifying who the suspects were.
On 1 June, 31 Palestinians were killed by Israeli fire as they went to receive food. Israel said it had fired warning shots towards several suspects who advanced towards troops.
Israel imposed a blockade on all supplies to Gaza in March, saying Hamas was seizing deliveries for its fighters, which the group denies. A global hunger monitor said in May that half a million people in the strip faced starvation. The IPC estimated that nearly 71,000 children under five were expected to be 'acutely malnourished', with 14,100 cases expected to be severe in the next 11 months.
The hubs are set up inside Israeli military zones, to which independent media have no access, and are run by GHF, a new group of mainly US contractors. Israel wants it to replace a system coordinated by the UN and international aid groups.
The UN and other humanitarian organisations have rejected the new system, saying the GHF will not be able to meet the needs of Gaza's 2.3 million people and that it allows Israel to use food as a weapon to control the population.
Associated Press and Reuters contributed to this report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies

Medscape

time22 minutes ago

  • Medscape

Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies

(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)

Patient Handling Equipment Market worth US$16.4 billion in 2030 with 5.8% CAGR
Patient Handling Equipment Market worth US$16.4 billion in 2030 with 5.8% CAGR

Yahoo

time31 minutes ago

  • Yahoo

Patient Handling Equipment Market worth US$16.4 billion in 2030 with 5.8% CAGR

DELRAY BEACH, Fla., June 9, 2025 /PRNewswire/ -- The global Patient Handling Equipment Market , valued at US$11.8 billion in 2024 stood at US$12.4 billion in 2025 and is projected to advance at a resilient CAGR of 5.8% from 2025 to 2030, culminating in a forecasted valuation of US$16.4 billion by the end of the period. The patient handling equipment market is experiencing steady growth, primarily driven by the increasing prevalence of chronic diseases such as neurological disorders & cardiovascular conditions. As the global population ages and chronic illnesses become common, the demand for patient handling equipment rises. Hospitals, rehabilitation centers, senior care facilities, and other end users are adopting advanced patient handling equipment to enhance patient care and reduce the risk of musculoskeletal injuries among healthcare professionals. Additionally, the growing obese population and the expansion of home healthcare services worldwide are fueling the demand for this equipment. Furthermore, the efforts to improve healthcare infrastructure in emerging nations, combined with integrating technologies like artificial intelligence, are creating new opportunities for companies in this sector. Download PDF Brochure: Browse in-depth TOC on "Patient Handling Equipment Market" 756 - Tables 52 - Figures 510 - Pages By type, the patient handling equipment market is segmented based on type into patient transfer devices, medical beds, mobility equipment, bathroom & toilet assist equipment, and stretchers & transport chairs. The patient transfer devices segment will dominate the market during the forecast period. This segment is categorized into patient lifts, slings, air-assisted lateral transfer mattresses, sliding sheets, and accessories. The growth of the patient transfer devices segment can be attributed to the rising number of patients with mobility disabilities and the increasing incidence of chronic diseases and age-associated comorbidities. By application, the patient handling equipment market is segmented into bariatric care, acute care, long-term care, rehabilitation care, and other applications. The rehabilitation care segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the rising establishment of rehab facilities in emerging economies and the growing requirement for post-op care. Rehabilitation care is vital in helping individuals regain their mobility and muscle strength. The utilization of rehab care across home healthcare, hospitals, and senior care facilities is also expected to fuel the market growth. By geography, the patient handling equipment market is segmented into regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, Europe accounted for the largest share of the market. Factors such as the rising incidence & prevalence of chronic diseases, favorable government initiatives to improve healthcare infrastructure, and the rising obesity cases are expected to contribute to market growth in the region. The rapidly growing geriatric population is also expected to fuel the growth of the elderly care facilities segment in the region. The presence of leading patient handling equipment manufacturers in the region is also a key growth driver. Request Sample Pages : Some of the prominent players operating in the market include Arjo (Sweden), Stryker Corporation (US), Baxter International, Inc. (US), Savaria Corporation (Canada), Drive Devilbiss Healthcare (US), Etac AB (Sweden), GF Health Products, Inc. (US), V. Guldmann A/S (Denmark), and Joerns Healthcare LLC (US), among others. Arjo (US): Arjo is one of the leading players in the patient handling equipment market in 2022. The company is involved in the manufacturing and supplying of patient handling equipment, including lateral transfer patient lifts, floor lifters and slings, standing & raising aids, walking aids, stretchers, medical beds repositioning products, and mattresses. Arjo sells its products in more than 100 countries across North America, Western Europe, and the Rest of the World. The company intends to broaden its business in the global market mainly through acquisitions and partnerships. For instance, in 2021, Arjo (Sweden) acquired AirPal (US) to strengthen its patient handling product portfolio. Baxter International, Inc. (US) Baxter International, Inc. is one of the leading player in the patient handling equipment market in 2022. The company manufactures important healthcare products, including smart bed systems; patient monitoring, sterile intravenous solutions; acute and chronic dialysis therapies; parenteral nutrition therapies; infusion systems and devices; inhaled anesthetics; generic injectable pharmaceuticals; and diagnostic technologies; as well as respiratory health devices. Baxter International, Inc. manufactures products in over 20 countries and sells them in over 100 countries. For more information, Inquire Now! Related Reports: Patient Monitoring Devices Market Patient Temperature Monitoring Market Physiotherapy Equipment Market Orthopedic Devices Market Rehabilitation Equipment Market Get access to the latest updates on Patient Handling Equipment Companies and Patient Handling Equipment Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio

UK's MHRA suspends Valneva's chikungunya vaccine for elderly
UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Yahoo

time2 hours ago

  • Yahoo

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

(Reuters) -UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above as a precautionary measure. The vaccine, IXCHIQ, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in February to protect people aged 18 years and above against chikungunya, but is not yet available in the UK market. "The decision to restrict the licence until further review is based on global data which has highlighted 23 cases of serious adverse reactions, including two cases reporting a fatal outcome, in people aged from 62 to 89 years of age who received the vaccine," the regulator said. The adverse events were reported in the French overseas territory of La Reunion, where a chikungunya outbreak was reported earlier this year. MHRA's decision comes after the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in May suspended the use of the vaccine in the age group. The French Government was the first to take the step in April.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store